Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$ADMA Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.17 up 21.43% YoY • Reported revenue of $124.39M up 1.98% YoY • ADMA Biologics reiterates its FY2026 financial guidance, expecting total revenue of $530 million to $560 million, Adjusted Net Income of $170 million to $200 million, and Adjusted EBITDA of $265 million to $300 million.
5

Price since post

Full Details

Advertisement|Remove ads.